Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Shibo Jiang and Guangyu Zhao.
Connection Strength

1.532
  1. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV. J Virol. 2018 09 15; 92(18).
    View in: PubMed
    Score: 0.196
  2. Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. PLoS One. 2015; 10(12):e0145561.
    View in: PubMed
    Score: 0.163
  3. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine. 2014 Apr 11; 32(18):2100-8.
    View in: PubMed
    Score: 0.143
  4. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One. 2013; 8(12):e81587.
    View in: PubMed
    Score: 0.141
  5. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol J. 2013 Aug 26; 10:266.
    View in: PubMed
    Score: 0.138
  6. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol. 2013 Sep; 87(17):9939-42.
    View in: PubMed
    Score: 0.137
  7. A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol. 2010 Apr; 23(2):211-9.
    View in: PubMed
    Score: 0.109
  8. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology. 2009 Oct 10; 393(1):144-50.
    View in: PubMed
    Score: 0.105
  9. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 2020 09 25; 369(6511):1603-1607.
    View in: PubMed
    Score: 0.056
  10. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018 Apr 24; 7(1):77.
    View in: PubMed
    Score: 0.048
  11. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum Vaccin Immunother. 2017 07 03; 13(7):1615-1624.
    View in: PubMed
    Score: 0.044
  12. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. J Virol. 2017 Jan 01; 91(1).
    View in: PubMed
    Score: 0.044
  13. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology. 2016 12; 499:375-382.
    View in: PubMed
    Score: 0.043
  14. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother. 2015; 11(5):1244-50.
    View in: PubMed
    Score: 0.038
  15. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol. 2014 Jun; 88(12):7045-53.
    View in: PubMed
    Score: 0.036
  16. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 2008 Mar 20; 26(13):1644-51.
    View in: PubMed
    Score: 0.024
  17. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol. 2008 Jan 15; 180(2):948-56.
    View in: PubMed
    Score: 0.023
  18. Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochem Biophys Res Commun. 2007 Jul 20; 359(1):174-9.
    View in: PubMed
    Score: 0.022
  19. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine. 2007 Apr 12; 25(15):2832-8.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.